Skip to main content

Table 2 Univariate and multivariate analysis of factors associated with overall survival and time to recurrence in GC patients

From: RETRACTED ARTICLE: Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway

 

Overall Survival

Time To Recurrence

Clinical Variables

HR (95% CI)

P value

HR (95% CI)

P value

Univariate analysis

 miR-939 (high versus low)

0.122 (0.053–0.281)

<0.001

0.228 (0.121–0.429)

<0.001

 SLC34A2 (high versus low)

4.555 (2.241–9.260)

<0.001

4.179 (2.247–7.769)

<0.001

 Gender (female versus male)

0.559 (0.294–1.060)

0.075

0.791 (0.441–1.420)

0.433

 Age (≥60 versus < 60 years)

1.188 (0.614–2.297)

0.609

1.063 (0.588–1.921)

0.839

 T status (T4 versus T1 + 2 + 3)

2.242 (1.182–4.254)

0.013

1.837 (1.042–3.239)

0.035

 N status (N2 + 3 versus N1 + 2)

6.324 (2.463–16.239)

<0.001

4.928 (2.301–10.555)

<0.001

 Clinical stage (III versus II)

14.407 (3.461–59.972)

<0.001

9.070 (3.250–25.313)

<0.001

 Tumor size (≥5 cm versus < 5 cm)

2.080 (1.097–3.947)

0.025

2.057 (1.164–3.631)

0.013

 Tumor grade (G3 versus G1 + 2)

1.371 (0.667–2.828)

0.389

1.354 (0.716–2.560)

0.351

Combination of miR-939 and SLC34A2

 II versus I

3.482 (0.778–15.581)

0.103

2.776 (0.971–7.939)

0.057

 III versus I

6.822 (1.801–25.842)

0.005

2.971 (1.074–8.219)

0.036

 IV versus I

24.212 (7.049–83.161)

<0.001

11.118 (4.688–26.368)

<0.001

Multivariate analysisa

 miR-939 (high versus low)

0.167 (0.070–0.398)

<0.001

0.328 (0.168–0.640)

0.001

 SLC34A2 (high versus low)

2.287 (1.050–4.981)

0.037

2.517 (1.276–4.965)

0.008

 T status (T4 versus T1 + 2 + 3)

1.642 (0.833–3.233)

0.152

1.403 (0.776–2.533)

0.262

 N status (N2 + 3 versus N1 + 2)

3.812 (1.426–10.188)

0.008

3.143 (1.418–6.966)

0.005

 Tumor size (≥5 cm versus < 5 cm)

1.784 (0.929–3.425)

0.082

1.754 (0.982–3.133)

0.058

Multivariate analysisb

Combination of miR-939 and SLC34A2

 II versus I

3.320 (0.734–15.015)

0.119

2.865 (0.980–8.376)

0.055

 III versus I

7.988 (2.077–30.727)

0.003

3.444 (1.224–9.689)

0.019

 IV versus I

15.959 (4.498–56.619)

<0.001

7.970 (3.249-19.546)

<0.001

T status (T4 versus T1 + 2 + 3)

1.697 (0.852–3.382)

0.133

1.423 (0.782–2.590)

0.249

N status (N2 + 3 versus N1 + 2)

3.862 (1.443–10.339)

0.007

3.157 (1.424–7.001)

0.005

Tumor size (≥5 cm versus < 5 cm)

1.833 (0.949–3.543)

0.071

1.789 (0.998–3.240)

0.055

  1. Combination of miR-939 and SLC34A2: I, High miR-939 and Low SLC34A2; II High miR-939 and High SLC34A2; III Low miR-939 and Low SLC34A2; IV Low miR-939 and High SLC34A2
  2. Analysis was conducted using univariate or multivariate Cox proportional hazards regression
  3. aMultivariate analysis of miR-939, SLC34A2, T status, N status and Tumor size
  4. bMultivariate analysis of the combination of miR-939 and SLC34A2, T status, N status and Tumor size
Back to article page

Molecular Cancer

ISSN: 1476-4598